TIDMIMM

RNS Number : 3228D

Immupharma PLC

28 June 2021

28 June 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.

The results of each resolution were as follows:

 
           Resolution                For       % For    Against    % Against   Withheld 
 1. To receive the accounts 
  of the Company for the 
  year ended 31 December 
  2020 together with the 
  reports thereon of the 
  directors and auditors 
  of the Company                  27,979,197   99.93    20,000       0.07      663,319 
                                 -----------  ------  ----------  ----------  --------- 
 2. To re-appoint Dr Stephane 
  Mery as a director of 
  the Company                     22,040,754   76.93   6,610,683     23.07      11,079 
                                 -----------  ------  ----------  ----------  --------- 
 3. To re-appoint Nexia 
  Smith & Williams as auditors 
  of the Company                  28,003,061   99.92    22,348       0.08      637,107 
                                 -----------  ------  ----------  ----------  --------- 
 4. That the directors 
  be authorised to allot 
  shares on the basis set 
  out in the Notice of Meeting    27,762,710   99.82    48,844       0.18      850,962 
                                 -----------  ------  ----------  ----------  --------- 
 5. To waive pre-emption 
  rights in respect of the 
  issue of the shares on 
  the basis set out in the 
  Notice of Meeting               27,759,210   99.81    52,344       0.19      850,962 
                                 -----------  ------  ----------  ----------  --------- 
 

As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,2975 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

End

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin 
 
    Stanford Capital Partners (Joint Broker)      +44 (0) 203 36 8 3550 
    Patrick Claridge 
    John Howes 
    Bob Pountney                                   +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKFBKKBKDBAB

(END) Dow Jones Newswires

June 28, 2021 06:03 ET (10:03 GMT)

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Immupharma.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Immupharma.